Abstract PS11-32: Mario-3 phase II study safety run-in evaluating a novel triplet combination of eganelisib (formerly IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)

Authors: Erika Hamilton, Arielle Lee, Rachel Swart, Gina Newton, Brenda O'Connell, Jennifer Roberts, Halle Zhang, Hatem Soliman

Published: 2021-02-15

DOI: 10.1158/1538-7445.sabcs20-ps11-32

Source: Full article